types based on the extent of central nervous system involvement.
Type 2, acute neuronopathic GD, is the most lethal form of the disease, with mortality generally occurring in the first months to years of life (Stone, Carey, et al., 2000; Stone, Tayebi, et al., 2000; Tezuk et al., 2017) .
GBA1 is located in a gene-rich region on chromosome 1q21 containing seven genes and two pseudogenes (Winfield, Tayebi, Martin, Ginns, & Sidransky, 1997) . A highly homologous GBA1 pseudogene (pGBA), with the same organization of exons and introns, is localted only 16 kb downstream (Horowitz et al., 1989) . In addition, MTX, a contigious gene just downstream of pGBA, is convergently transcribed and encodes metaxin, a protein located on the outer mitichondial membarane. MTX also has a homologous pseudogene, located downstream of GBA (Armstrong, Komiya, Bergman, Mihara, & Bornstei, 1997; Long, Winfield, Adolph, Ginns, & Bornstein, 1996) . The close proximity of these genes and their homologous pseudogenes leads to relatively frequent recombination events (Mazzarella & Schlessinger,1998; Tayebi et al., 2003) . Today, more than 300 unique mutations in GBA1 have been descibed, including both point mutations and more complex recombinant alleles (Hruska, LaMarca, Scott, & Sidransky, 2008) .
Traditionally, GD has been understood to be inherited in an autosomal recessive manner. However, that model has been expanded to include recent cases with non-traditional inheritance. In one example, a child with paternal uniparental disomy of chromosome 1 was found to have both GD and Charcot-Marie-Tooth disease (Benko et al., 2008) . De novo germline mutations at amino acid Leu444 (p.Leu483) were reported in two other infants with type 2 GD, where no mutations were identified in either mother (Saranjam et al., 2013) .
These studies have spurred physicians to consider alternative means of inheritance when presented with a challenging case. In this report, we present a child with type 2 GD whose phenotype likely arose from a different germline mutation.
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Blood and/or fibroblast samples were collected from the proband and his parents with informed consent under an NHGRI Institute Review Board-approved clinical protocol.
| Case report
The proband was full-term male born to non-consanguineous Caucasian parents by normal home delivery with a birth weight of 3.40 kg. He was noted to have peeling skin, as well as inspiratory stridor and tachypnea immediately after birth, and required observation in the hospital. Both symptoms resolved, and the infant was discharged home. He was breastfed for 2 months, but due to poor weight gain breast milk was fortified with formula to increase calories.
At 2.5 months of age his increasing stridor and poor weight gain necessitated evaluations by multiple specialists, including gastroenterology and otolaryngology. He was diagnosed with laryngomalacia and the parents were told that the condition was expected to resolve.
At 3.5 months, he was hospitalized for failure-to-thrive and received nasogastric feeds. At this time, he also had an abnormal swallow study.
While awaiting discharge he went into respiratory arrest and was intubated. After several repeated failed attempts at extubation, laryngoscopy was performed, demonstrating paradoxical vocal chord movement, and botox was administered to the vocal cords twice.
However extubation was still unsucessful, and both a tracheostomy and gastrostomy tube placement were performed. By age 4 months, he lost the ability to move his eyes, and he developed generalised myoclonic jerks which initially did not show as seizure activity on the EEG. Two abdominal ultrasounds showed an enlarged spleen. By age 5 months, the EEG demonstrated seizure activity. The parents requested evaluation by an independent neurologist to consider a lysosomal storage disease. The diagnosis of type 2 GD was confirmed by whole exome sequencing when the proband was 6 months old. He was started on Ambroxol at 6 months of age, at 12 mg/kg twice daily.
However his seizures and myoclonus worsened and became difficult to control, and he became ventilator-dependent. His parents opted to place the proband in hospice care, and despite excellent supportive care, he passed away at the age of 17 months due to respiratory failure from status epilepticus.
2.2 | Genomic DNA and cDNA sequencing GBA1 sequencing was performed on genomic DNA from the proband and his parents. DNA was extracted from leukocytes of the parents, and from fibroblasts from the proband. GBA1 gene was amplified from genomic DNA in three fragments encompassing exons 1-5, 5-7, and 8-11 as previously described (Stone, Carey, et al., 2000; Stone, Tayebi, et al., 2000) , and individual exons were amplified as well. Amplified fragments were purified using a QIAquick PCR Purification Kit (Qiagen, Santa Clarita, CA), and cycle sequencing was performed using both forward and reverse primers with a DyeTerminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA), on an ABI Prism 3730XL DNA Analyzer (Applied Biosystems). The sequencing data was analyzed by SeqScape v2.6 using GeneBank NG_009783.1 as the reference sequence. To confirm the findings in the mother and proband, cDNA was made from fibroblast RNA using Supercript IV (Life Technologies, Carlsbad, CA) to synthesis the first strand. The 1.7 kb cDNA was amplified using exon 1 forward and exon 11 reverse primers (Stone, Carey, et al., 2000; Stone, Tayebi, et al., 2000) , cleaned and then sequenced.
| Protein analysis
Frozen fibroblast pellets were homogenized in 100 µl of Citratephosphate buffer at pH 4.2, with 0.25% Triton X-100, with a proteaseinhibitor tablet (Roche Diagnostics, Indianapolis, IN). Cells were disrupted by two ten-second sonication pulses at 50% amplitude, and cell debris was removed by centrifugation at 5,000 rpm for 5 min.
Western blotting was performed and glucocerebrosidase levels were quantified as previously described (Westbroek et al., 2016) , using β-actin (abcam 20272, 1:4000) as the loading control.
| Enzyme activity assay
Glucocerbrosidase activity in the mother and proband was analyzed using 4-methylumbelliferyl-β-D (4-MU) glucopyranoside substrate, as previously described (Raghavan, Topol, & Kolodny, 1980; Westbroek et al., 2016) , with the following modifications. Reactions were performed in pH 4.2 citrate-phosphate buffer and incubated for 2.5 hr at 37°C.
Fluorescence was measured at λ ex = 365 nm and λ em = 448 nm.
| Genomic realtime PCR
Quantitative realtime PCR was performed on genomic DNA isolated from cultured fibroblasts from the proband, the mother, and a control as described (Velayati, Knight, Stubblefield, Sidransky, & Tayebi, 2011) .
| RESULTS
Analysis of the proband's DNA revealed two mutations, Arg257Gln (c.887G>A; p.arg296gln) and Gly202Arg (c.721G>A; p.gly241arg). The Arg257Gln mutation was identified in the paternal DNA. However, the Gly202Arg mutation, presumed to be from the mother, was not detected in the maternal genomic DNA. While the initial genotyping was performed using next-generation technology by a commercial laboratory, genomic DNA isolated from blood and fibroblasts was Sanger-sequenced, confirming the initial results (Figure 1a ). The proband and mother's results were also confirmed by sequencing cDNA made from fibroblast RNA (results not shown). Recombination events between GBA1 and its highly homologous pseudogene located 16 kb downstream are relatively common and are often found in patients with type 2 GD . To confirm there were no recombinations in the proband that were not detected by sequencing, quantitative real-time PCR was performed on genomic DNA. No deletions or duplications were detected in any of the regions targeted by our probes (Figure 1b) .
GCase levels and activity were analyzed in fibroblasts from the mother and proband (Figure 2) . Protein levels and activity in the mother's fibroblasts were in the control range, while the proband had almost undetectable levels, as typically seen with type 2 GD.
| DISCUSSION
In a study conducted by Saranjam et al. (2013) , de novo or germline mutation of Leu444Pro (c.1448T>C;p.leu483pro) was reported in two patients with type 2 GD from two unique families. It was noted FIGURE 1 Genotyping results: (a) Chromatograms showing DNA sequencing results for proband and parents. Genomic DNA isolated from fibroblasts (proband) and leukocytes (mother and father) demonstrated mutations Gly202Arg and Arg257Gln in the proband, no mutations in the mother, and the Arg257Gln mutation in the father. (b) Quantitative genomic realtime PCR of GBA1 and GBAP, looking for possible recombination between GBA1 and it's pseudogene. The probes are shown in order, beginning from the region upstream of GBA1 to the 3′ end of GBAP. WT: Control sample with no known recombinations, used to normalize the data. Red lines indicate range of variation in controls. [Color figure can be viewed at wileyonlinelibrary.com]
